Trade AVXL stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Anavex Life Sciences Corp. (AVXL) is trading at US$1.61, down 2.43% today as of Oct 6, 14:20 EDT. The company has a market capitalisation of US$300.34M. Over the past 52 weeks, AVXL has traded between US$1.61 and US$10.38. On Syfe you can trade AVXL with $0 commission and add it to your watchlist.
| Previous close | US$1.65 |
|---|---|
| Market cap | US$300.34M |
| 52-week range | US$1.61 – US$10.38 |
| Volume | 2.02M |
| Exchange | US |
Anavex Life Sciences Corp.
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Year: 2006
Anavex Life Sciences Regains Nasdaq Compliance After Filing Quarterly Reports
Sep 2, 9:37 PM · MT Newswires
Sector Update: Healthcare Stocks Advance Late Afternoon
Aug 25, 7:57 PM · MT Newswires
Anavex Life Sciences Shares Rise After Q3 Swings to Profit
Aug 25, 6:52 PM · MT Newswires
Anavex Life Sciences Submits Plan to Regain Compliance With Nasdaq Timely Filing Rule
Jul 20, 4:31 PM · MT Newswires
Stay on top of AVXL
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
